J. Dwyer

发表

Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.

H. Parving, D. de Zeeuw, H. L. Lambers Heerspink, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Labile Hypertension: Characteristics of a Referred Cohort

Matthew R. Elliott, W. Haley, J. Dwyer, 2013, Clinical and experimental hypertension.

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.

J. McMurray, T. Greene, D. Wheeler, 2021, Kidney international.

Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

H. Parving, J. Coresh, A. Levey, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience

J. Lewis, J. Arroyo, A. Guide, 2021 .

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Deepak L. Bhatt, Lawrence A Leiter, M. Sabatine, 2019, The lancet. Diabetes & endocrinology.

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

Deepak L. Bhatt, Lawrence A Leiter, R. Diaz, 2020, The New England journal of medicine.

Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook.

J. Lewis, J. Dwyer, 2013, The Medical clinics of North America.

When Diabetics Don't Read the Textbook

J. Lewis, J. Dwyer, 2013 .

Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study

H. Parving, G. Remuzzi, J. Lewis, 2011, Cardiorenal Medicine.

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial

Marc P. Bonaca, Lawrence A Leiter, A. Keech, 2019, Circulation.

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

M. Pfeffer, C. Held, J. McMurray, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

J. McMurray, T. Greene, D. Wheeler, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.

J. Dwyer, L. Brumble, S. Alvarez, 2009, The AIDS reader.

Evaluation of Renal Artery Stenosis in Dialysis Patients

J. Lewis, J. Dwyer, B. Greco, 2009, Seminars in dialysis.

Does renal dysfunction and method of bridging support influence heart transplant graft survival?

J. Stulak, I. Feurer, M. Keebler, 2014, The Annals of thoracic surgery.

Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome.

Matthew R. Elliott, J. Dwyer, C. Cortese, 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Integrating biomarkers to predict renal and cardiovascular drug efficacy

H. Parving, G. Remuzzi, H. Heerspink, 2016 .

Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes

H. Parving, G. Remuzzi, D. de Zeeuw, 2016, Diabetes, obesity & metabolism.

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

R. Atkins, J. Lewis, D. de Zeeuw, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important?

J. Lewis, J. Dwyer, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ferric citrate in end-stage kidney disease as a phosphate binder and source of iron: a review of clinical trials

D. Jalal, J. Dwyer, B. Greco, 2015 .

Pyridoxamine Dihydrochloride in Diabetic Nephropathy (PIONEER-CSG-17): Lessons Learned from a Pilot Study

J. Lewis, J. Dwyer, B. Greco, 2014, Nephron.

Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice.

P. Whelton, M. Rocco, Mahboob Rahman, 2020, JAMA internal medicine.

High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function.

R. McNeil, M. Bridges, J. Dwyer, 2009, AJR. American journal of roentgenology.

In‐Center Thrombolysis for Clotted AV Access: A Cohort Review

P. Bream, G. Schulman, J. Dwyer, 2013, Seminars in dialysis.

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Deepak L. Bhatt, Lawrence A Leiter, M. Sabatine, 2021, Diabetes Care.

Original Investigation The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial

J. Lewis, T. Greene, M. Koury, 2015 .

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

J. Lewis, T. Greene, M. Koury, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data

R. Rodby, J. Dwyer, Marvin V Sinsakul, 2014, Expert review of clinical pharmacology.

Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis

E. Siew, J. Dwyer, Huma Fatima, 2012, Clinical kidney journal.

Multi-Nephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience.

J. Lewis, J. Arroyo, A. Guide, 2021, Journal of cardiac failure.

Edinburgh Research Explorer Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease

C. Cannon, D. Rader, M. Banach, 2018 .

OP-NDTJ200238 1..12

J. McMurray, T. Greene, D. Wheeler, 2020 .

Diabetic Proteinuria Revisited: Updated Physiologic Perspectives

J. Lewis, I. Raz, S. Heyman, 2022, Cells.

Once‐Daily Plazomicin for Complicated Urinary Tract Infections

L. Miller, K. Krause, F. Wagenlehner, 2019, The New England journal of medicine.

We Give Too Much Intravenous Iron

J. Dwyer, 2016, Seminars in dialysis.

Interns' work hours.

Marc-David Cohen, J. Dwyer, 2005, The New England journal of medicine.

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.

J. Lewis, M. Koury, M. Kaplan, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs

J. Lewis, R. Rodby, J. Dwyer, 2015, Expert review of pharmacoeconomics & outcomes research.

CHAPTER 64 – Thromboembolic Renovascular Disease

J. Lewis, J. Dwyer, B. Greco, 2010 .

COVID-19 and the Inpatient Dialysis Unit: Managing Resources During Contingency Planning Pre-Crisis.

T. Ikizler, A. Burgner, J. Dwyer, 2020, Clinical journal of the American Society of Nephrology : CJASN.

192Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Deepak L. Bhatt, Lawrence A Leiter, M. Sabatine, 2019, European Heart Journal.

The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients

J. Lewis, T. Greene, M. Koury, 2012, Nephron Clinical Practice.

Rationale and study design of a three‐period, 58‐week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

J. Lewis, M. Koury, G. Schulman, 2013, Hemodialysis international. International Symposium on Home Hemodialysis.

AKI in an HIV patient.

A. Fogo, J. Dwyer, Mariu Carlo, 2013, Journal of the American Society of Nephrology : JASN.

Membranous nephropathy with crescents.

J. Lewis, A. Fogo, J. Dwyer, 2011, Journal of the American Society of Nephrology : JASN.

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

A. Jubb, K. Krause, G. Talbot, 2019, The New England journal of medicine.

OP-NDTJ180390 265..319

M. Pfeffer, C. Held, J. McMurray, 2020 .

Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.

M. Koury, A. Fogo, R. Zent, 2007, Clinical nephrology.

Assessment of Blood Pressure: Techniques and Implications From Clinical Trials.

Dia R Waguespack, J. Dwyer, Jamie P Dwyer, 2019, Advances in chronic kidney disease.

Estimating baseline kidney function in hospitalized patients with impaired kidney function.

J. Schildcrout, E. Siew, J. Peterson, 2012, Clinical journal of the American Society of Nephrology : CJASN.

Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.

P. Whelton, M. Rocco, P. Kimmel, 2019, Journal of the American Society of Nephrology : JASN.

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.

C. Cannon, D. Rader, M. Banach, 2018, Kidney international.

The role of survival motor neuron protein (SMN) in protein homeostasis

C. Cannon, D. Rader, M. Banach, 2018, Cellular and Molecular Life Sciences.

Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data

J. Lewis, R. Rodby, J. Dwyer, 2015, Drugs in R&D.

Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

J. Lewis, T. Greene, M. Koury, 2015, Journal of the American Society of Nephrology : JASN.

Ferric citrate: a novel phosphate-binding agent

J. Lewis, J. Dwyer, K. Umanath, 2013, Expert review of endocrinology & metabolism.

Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents

J. Lewis, A. Fogo, J. Dwyer, 2021, Glomerular Diseases.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

B. Davis, M. Woodward, F. Farzadfar, 2022, Heart.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).

Anna C. Porter, K. Sink, M. Rocco, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee.

J. Lewis, A. Burgner, J. Dwyer, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Optimizing blood pressure control in patients with nondiabetic glomerular disease.

J. Lewis, J. Dwyer, K. Umanath, 2014, Advances in chronic kidney disease.

Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis

J. Lewis, T. Greene, D. Jalal, 2017, Hemodialysis international. International Symposium on Home Hemodialysis.

Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial

S. Oparil, W. Cushman, A. Cheung, 2016, Hypertension.

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Lawrence A Leiter, M. Sabatine, D. McGuire, 2021, JAMA cardiology.

Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants

Walter T Ambrosius, Laura Lovato, Jeffrey Bates, 2018, PloS one.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Sabatine, 2022, Diabetes care.

244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Sabatine, 2019, Diabetes.

Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study

Mahboob Rahman, D. Goff, Lawrence J. Fine, 2017, Hypertension.

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

P. Mol, D. de Zeeuw, H. Heerspink, 2017, Clinical journal of the American Society of Nephrology : CJASN.

Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study

P. Whelton, M. Rocco, Mahboob Rahman, 2022, Kidney360.

Kidney Dysfunction and Left Ventricular Assist Device Support: A Comprehensive Perioperative Review

M. Keebler, Dia R Waguespack, S. Maltais, 2015, Cardiorenal Medicine.

Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial)

P. Whelton, S. Oparil, W. Cushman, 2018, Hypertension.

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials

J. Bruss, J. Dwyer, M. Lacy, 2018, Pharmacotherapy.

The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis .

J. Lewis, T. Greene, M. Koury, 2017, Clinical nephrology.

Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy

P. Blankestijn, H. Heerspink, F. Visseren, 2016, Diabetes, obesity & metabolism.

Decentralized clinical trials in the trial innovation network: Value, strategies, and lessons learned

Terri L. Edwards, K. Wiley, K. Lane, 2023, Journal of Clinical and Translational Science.

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

M. Landray, J. Chan, K. Mahaffey, 2023, Nature Medicine.

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial

D. Wheeler, G. Law, H. Heerspink, 2023, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Labile Hypertension: Characteristics of a Referred Cohort

W. Haley, J. Dwyer, Jose Soto Soto, 2013, Clinical and experimental hypertension.

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

Deepak L. Bhatt, M. Sabatine, D. Morrow, 2023, Diabetes care.

Proteinuria in Type 2 Diabetic Patients with Renal Impairment: The Changing Face of Diabetic Nephropathy

R. Atkins, J. Lewis, A. Reutens, 2010, Nephron Clinical Practice.

Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study

A. Agiro, J. Dwyer, Pooja S. Desai, 2023, Expert review of pharmacoeconomics & outcomes research.

New Directions in Phosphorus Management in Dialysis.

E. Kelepouris, J. Dwyer, 2022, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

Clinical Practice: Original Paper Pyridoxamine Dihydrochloride in Diabetic Nephropathy (pioneer-csg-17): Lessons Learned from a Pilot Study

J. Dwyer, M. Sika, K. Umanath, 2022 .

Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study

A. Agiro, J. Dwyer, Pooja Desai, 2023, Advances in therapy.